Ranolazine is a novel antianginal agent capable of producing anti-ischemic effects at
plasma concentrations of 2 to 6 μM without a significant reduction of heart rate or blood …

Background—Ranolazine is a novel antianginal agent capable of producing antiischemic
effects at plasma concentrations of 2 to 6 μmol/L without reducing heart rate or blood …

Ranolazine is a Food and Drug Administration–approved antianginal agent. Experimental
and clinical studies have shown that ranolazine has antiarrhythmic effects in both ventricles …

Extended-release ranolazine (ranolazine ER)[Ranexa®] is a piperazine derivative with a
novel mechanism of action that was recently approved in the EU for use as add-on therapy …

The aim of this study was to investigate the cellular electrophysiological effects of ranolazine
on action potential characteristics. The experiments were carried out in dog and human …

In recent years there has been a major reorientation of drug therapy for cardiac arrhythmias,
its changing role, and above all, a radical change in the class of arrhythmia drugs because …

We tested the effect of the antianginal agent ranolazine on ventricular arrhythmias in an
ischemic model using two protocols. In protocol 1, anesthetized rats received either vehicle …

Ranolazine was developed as an antianginal agent and was approved by the Food and
Drug Administration in 2006 for use in chronic stable angina pectoris. Experimental and …

Ranolazine is a novel anti‐ischemic drug that prolongs the QT interval. To evaluate the
potential mechanisms and consequences, we studied:(i) Ranolazine's effects on HERG and …

Ranolazine, which was approved by the US Food and Drug Administration in January 2006,
provides a mechanism of action to treat ischemia that has not hitherto been available …